The high risk for early events observed in certain subgroups of patients suggests that combined information on IL6 genotype, tumour ER-status, and breast cancer treatment may represent a tool for identifying patients who require more personalised treatment, potentially using inhibitors of NF-κβ or IL-6. Here, NFKB1 is linked to breast cancer.